HOME > News

We wish to inform you that law no. 196/03 protects people
and other subjects as concerns the use of personal details.
Edit email address
Invialid email
Email Sent
Accept privacy law
Chiesi enters into an Exclusive ex-US Partnership with Protalix BioTherapeutics for the Development and Commercialization of PRX-102 (pegunigalsidase...
Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A protein Protalix to receive $25 million...
Chiesi is Top Employer again!
Alberto, Paolo and Andrea Chiesi winners of the “Entrepreneur of the year 2015” Award
Special Mention to Holoclar at the Italian Galeno Award
COPD indication for Foster pMDI
Double-digit growth and internal expansion for the Chiesi Group